Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Carnosine is a naturally occurring compound with a potential health benefits. In animal studies, carnosine supplementation reduces manifestation of chronic civilization diseases, regulates subclinical inflammation, protein glycation and lipid & glucose metabolism. Our preliminary data showed the relationship between insulin resistance and carnosine content in human skeletal muscle. Based on these unique results we plan to perform intervention study aimed at identifying effects of carnosine on insulin sensitivity and secretion, which might reduce the development of T2D in obese. Similar metabolic effects of vitamin D3 were associated with expression of specific miRNAs. Circulating miRNAs related to carnosine action are unknown. The putative positive effects of carnosine on insulin sensitivity and secretion in obese patients might have a tremendous impact in prevention of type 2 diabetes. Identification of miRNAs associated with carnosine action could provide predictors of successful therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CARNOSINE | Experimental | 3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1) |
|
| placebo | Placebo Comparator | 3 months placebo intake - taken twice a day (1-0-1) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Carnosine | Dietary Supplement |
|
| Measure | Description | Time Frame |
|---|---|---|
| oxidative stress | AGEs and lipid peroxidation products | within one year |
| chronic systemic inflammation | circulating hsCRP | one year |
| Measure | Description | Time Frame |
|---|---|---|
| level of glucose intolerance | detected by the oral glucose tolerance test. expressed as 2h glucose, area under the glycemic curve, QUICKI index, HOMA-IR | within 10 months |
| Measure | Description | Time Frame |
|---|---|---|
| muscle carnosine content | assessed by 1H-MRS of muscle in vivo (7T Magnet, Siemens, Germany) it will be expressed relative to creatine signal. | within 9 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jozef Ukropec, PhD | Institute of experimental endocrinology SAS | Principal Investigator |
| Barbara Ukropcova, MD, PhD | Faculty of Medicine Comenius University & Institute of Experimental Endocrinology SAS | Study Director |
| Boris Krahulec, MD, PhD | University Hospital in Bratislava | Study Chair |
| Barbora deCourten, MD, MPH, PhD, FRACP | Monash University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Univeristy Hospital in Bratislava | Bratislava | 81369 | Slovakia | |||
| Institute of Experimental Endocrinology Slovak Academy of Sciences |
Not provided
| ID | Term |
|---|---|
| D008659 | Metabolic Diseases |
| D003924 | Diabetes Mellitus, Type 2 |
| D002318 | Cardiovascular Diseases |
| ID | Term |
|---|---|
| D009750 | Nutritional and Metabolic Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002336 | Carnosine |
| ID | Term |
|---|---|
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D004151 | Dipeptides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Bratislava |
| 83306 |
| Slovakia |
| D009842 |
| Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |